29 Sep 2021 by admin in UncategorizedComments Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
28 Sep 2021 by admin in UncategorizedComments Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)
27 Sep 2021 by admin in UncategorizedComments Syros Announces Appointment of Conley Chee as Chief Commercial Officer
20 Sep 2021 by admin in UncategorizedComments Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
14 Sep 2021 by admin in UncategorizedComments Alebund Pharmaceuticals Raises $54.5 Million in Series B+ Financing Round to Fuel Development of Renal Disease Treatment
13 Sep 2021 by admin in UncategorizedComments Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases
13 Sep 2021 by admin in UncategorizedComments Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
13 Sep 2021 by admin in UncategorizedComments Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
10 Sep 2021 by admin in UncategorizedComments Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
09 Sep 2021 by admin in UncategorizedComments Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
